AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35581905
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy or metformin sequentially followed by glipizide and basal insulin
Trial: 33684919
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH (100 μg/kg/day)
Trial: 33684919
Drug: Standard-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose GH (33 μg/kg/day)
Trial: 33684919
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH (11 μg/kg/day)
Trial: 33256192
Drug: Nd:YAG radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG radiation combined with fluoride gel
Trial: 34465476
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies against pertussis toxin (PT) measured with the CDC/FDA ELISA
Trial: 32446176
Drug: safinamide 50
RxNorm normalized name: safinamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 50 mg/day (S50)
Trial: 32446176
Drug: safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 100 mg/day (S100)
Trial: 34173895
Drug: Supportive counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive counseling (SC) plus Life-Steps medication adherence counseling
Trial: 36219589
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention using printed message cards about the quadrivalent HPV vaccine (n = 118)
Trial: 32419645
Drug: ColdZyme Mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ColdZyme Mouth Spray
Trial: 32419645
Drug: ColdZyme Mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ColdZyme Mouth Spray (good compliance)
Trial: 32419645
Drug: ColdZyme Mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ColdZyme Mouth Spray (poor compliance)
Trial: 32419645
Drug: ColdZyme Mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ColdZyme Mouth Spray (overall)
Trial: 34898069
Drug: Prostatic massage
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostatic massage twice a week (Group A)
Trial: 34898069
Drug: Biofeedback and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback and electrical stimulation 5 times a week combined with prostatic massage twice a week (Group C)
Trial: 34337917
Drug: As needed
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As needed propofol administration
Trial: 34337917
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol (5 mg kg‐1 h‐1)
Trial: 33315051
Drug: AKB‐9778 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKB‐9778 (subcutaneous treatment)
Trial: 33315051
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular AKB‐9778
Trial: 33066972
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous iron therapy
Trial: 35438278
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2g 8 hourly) for five days
Trial: 35438278
Drug: Thiamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (200 mg 12 hourly) for five days
Trial: 36397218
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (once every other day, 3 times a week for 5 weeks)
Trial: 36397218
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medication therapy (control group)
Trial: 32452352
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every 2 weeks (ADAQ2W)
Trial: 36448974
Drug: Intrathecal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal oxytocin (100 μg)
Trial: 34315283
Drug: OPUS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPUS treatment after implementation
Trial: 34276366
Drug: Norepinephrine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (0.5 mg/h, maximum 3 mg/h) plus albumin (20–40 g/day)
Trial: 34276366
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 mg three times/day, maximum 12.5 mg three times/day) plus octreotide (100 μg/6 h, maximum 200 μg/6 h) plus albumin (20–40 g/day)
Trial: 35065634
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU of OXT vaginal gel daily for eight weeks
Trial: 33109148
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion program (biweekly group education sessions and a 12-week individual behavioral modification for oral hygiene course)
Trial: 33109148
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion program
Trial: 34825740
Drug: PARO robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARO robot twice a day (Group 1)
Trial: 34108672
Drug: Vedolizumab 600
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab 600 mg
Trial: 32108044
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - 500 µg fluticasone propionate twice daily
Trial: 32058435
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for S. aureus carriers)
Trial: 32058435
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for noncarriers)
Trial: 36352204
Drug: 0.5-mg pramipexole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg pramipexole
Trial: 34465833
Drug: Urea +
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea + Biochar (BC) (10 Mg ha-1)
Trial: 34465833
Drug: Urea +
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea + Biochar (BC) + Urease Inhibitor (UI) (1 L ton-1)
Trial: 34465833
Drug: Biochar (BC)
RxNorm normalized name: COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochar (BC) (10 Mg ha-1)
Trial: 32755115
Drug: Anti-IL-5 treatments
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-IL-5 treatments (mepolizumab, benralizumab, reslizumab)
Trial: 34334142
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention
Trial: 34285768
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy sessions (tr‐MI, N = 39)
Trial: 34285768
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment as usual (TAU, N = 35)
Trial: 34285768
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy sessions (tr‐MI)
Trial: 34285768
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment as usual (TAU)
Trial: 32267934
Drug: Triglycerides <1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides <1 mmol/L (<89 mg/dL)
Trial: 32267934
Drug: Triglycerides 2.0-2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides 2.0-2.9 mmol/L (177-265 mg/dL)
Trial: 32267934
Drug: Triglycerides 3.0-3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides 3.0-3.9 mmol/L (266-353 mg/dL)
Trial: 32267934
Drug: Triglycerides 4.0-4.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides 4.0-4.9 mmol/L (354-442 mg/dL)
Trial: 32267934
Drug: Triglycerides ≥5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides ≥5 mmol/L (≥443 mg/dL)
Trial: 32267934
Drug: Plasma triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma triglycerides <2.0 mmol/L (77 mg/dL)
Trial: 32267934
Drug: Plasma triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma triglycerides 2.0-4.9 mmol/L (177-442 mg/dL)
Trial: 32267934
Drug: Plasma triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma triglycerides ≥5.0 mmol/L (443 mg/dL)
Trial: 32267934
Drug: Remnant cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remnant cholesterol <0.5 mmol/L (19 mg/dL)
Trial: 32267934
Drug: Remnant cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remnant cholesterol 0.5-1.4 mmol/L (19-57 mg/dL)
Trial: 32267934
Drug: Remnant cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remnant cholesterol ≥1.5 mmol/L (58 mg/dL)
Trial: 36319912
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg in 100 mL normal saline)
Trial: 36319912
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (100 mL)
Trial: 36220712
Drug: Adoptive Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive Immunotherapy with CD25/CD71 allodepleted donor T cells (ADTs)
Trial: 32147032
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 200000 IU vitamin D supplement (two injections, one at week 0 and another at week 4)
Trial: 35788212
Drug: Control limb
RxNorm normalized name: BANDAGE TUBULAR ELAST TUBIFAST LG LIMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control limb (no treatment)
Trial: 35766592
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg propofol (group P)
Trial: 35766592
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg lidocaine 2% (group L)
Trial: 35919499
Drug: Traditional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional group (50 patients) receiving conventional treatment
Trial: 32819331
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) program covering six techniques in 4 sessions (30 min each), with or without pharmacotherapy.
Trial: 32819331
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified in detail, but implied to be standard care or pharmacotherapy).
Trial: 35082179
Drug: Laser-grooved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-grooved treatment
Trial: 35082179
Drug: Sulfuric-acid-etched treatment
RxNorm normalized name: Sulfuric Acid
DrugBank: Sulfuric acid (DB11309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfuric-acid-etched treatment
Trial: 35082179
Drug: Sandblasted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted treatment
Trial: 34733185
Drug: Music Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Assisted Relaxation (MAR) protocol, a music therapy technique composed of entrained live music combined with a guided relaxation and/or the use of imagery
Trial: 35801801
Drug: Oral sulfate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfate tablet (OST)
Trial: 32157599
Drug: DB-020 (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DB-020 (sodium thiosulfate pentahydrate in 1% sodium hyaluronate) administered via intratympanic injection
Trial: 32080811
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg of PL-ASA in fasted state
Trial: 32080811
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg of PL-ASA in fed state
Trial: 35946981
Drug: Tretinoin 0.05%
RxNorm normalized name: TRETINOIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.05% lotion (Altreno)
Trial: 35946981
Drug: Generic 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic 0.05% cream
Trial: 35337317
Drug: Objective Structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective Structured Clinical Examination (OSCE) assessment method for Kampo medicine
Trial: 32350185
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% zinc oxide paste, applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Trial: 32350185
Drug: Improvised zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvised zinc preparation (1%), applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Trial: 32350185
Drug: Improvised zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvised zinc preparation (1%)
Trial: 32350185
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment offered by cancer hospital (Control group)
Trial: 36062848
Drug: Dilemma‐focused therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilemma‐focused therapy
Trial: 33897217
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment for people with depression
Trial: 34281611
Drug: Lower Extremity
RxNorm normalized name: lymphedema garments, lower extremity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower Extremity Constraint-Induced Movement Therapy (LE-CIT) for 2.5 h/day for 15 consecutive days, including intensive supervised training, shaping strategy for motor training, and a transfer package (plus 30 min).
Trial: 36359533
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy in the cervical spine and diaphragm, in combination with breathing reeducation exercises
Trial: 36359533
Drug: Cervical spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical spine manual therapy or usual physical therapy care
Trial: 32712663
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (PET) with valganciclovir for 100 days
Trial: 32697707
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 45 min; n = 12)
Trial: 36474770
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg S201086/GLPG1972
Trial: 36474770
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg S201086/GLPG1972
Trial: 36474770
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg S201086/GLPG1972
Trial: 34414430
Drug: No rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rate control drugs
Trial: 33950868
Drug: Anterior approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior approach injection (54 patients)
Trial: 33950868
Drug: Posterior approach
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior approach injection (41 patients)
Trial: 33162294
Drug: Slope-configured implants
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slope-configured implants (test group)
Trial: 33162294
Drug: Regular-configured implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-configured implants (control group)
Trial: 35781462
Drug: 1‰ PL‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‰ PL‐5 spray
Trial: 35781462
Drug: 2‰ PL‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‰ PL‐5 spray
Trial: 35781462
Drug: 4‰ PL‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‰ PL‐5 spray
Trial: 35781462
Drug: PL‐5 spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL‐5 spray
Trial: 33988881
Drug: Vismodegib treatment
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib treatment
Trial: 35801741
Drug: 4‐hour 1 + 2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐hour 1 + 2L bowel preparation regimen
Trial: 35801741
Drug: 6‐hour 1 + 2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐hour 1 + 2L bowel preparation regimen
Trial: 35801741
Drug: 4‐hour 0 + 2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐hour 0 + 2L bowel preparation regimen
Trial: 34724085
Drug: Standard-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose radiotherapy (3.0 Gy total, 0.5 Gy twice weekly)
Trial: 34724085
Drug: Very-low-dose radiotherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose radiotherapy (0.3 Gy total, 0.05 Gy twice weekly)
Trial: 33374006
Drug: Rifapentine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (specific dosage not mentioned)
Trial: 32056507
Drug: CT-based implant
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based implant motion analysis (CTMA) using surface anatomy of the pelvis
Trial: 32056507
Drug: CT-based implant
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based implant motion analysis (CTMA) using beads
Trial: 32056507
Drug: CT-based implant
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based implant motion analysis (CTMA)
Trial: 32297782
Drug: 6 mg/mL
RxNorm normalized name: phenol 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/mL nicotine e‐liquid
Trial: 32297782
Drug: 12 mg/mL
RxNorm normalized name: niacin 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/mL nicotine e‐liquid
Trial: 32122230
Drug: Vortioxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10 mg b.i.d.)
Trial: 33739883
Drug: HDR‐2 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDR‐2 (900 mg per day for 8 weeks)
Trial: 33739883
Drug: Placebo (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (900 mg per day for 8 weeks)
Trial: 35760720
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg every 2 weeks)
Trial: 35872448
Drug: Real tDCS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real tDCS stimulation (anodal electrical stimulation at 2 mA for 20 min once daily for 7 days)
Trial: 33550243
Drug: Enteral DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral DHA supplementation (60 mg/kg/day)
Trial: 32859615
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and Metformin
Trial: 33493373
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with an opioid
Trial: 32352250
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate gel 0.5%
Trial: 32352250
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate suspension 1%
Trial: 34404290
Drug: Pimavanserin augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin augmentation
Trial: 34404290
Drug: Pimavanserin augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin augmentation of antipsychotics
Trial: 32869527
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-tests (HIVST) distributed in intervention clusters
Trial: 33574125
Drug: Imeglimin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imeglimin (1,000 mg twice daily)